CCMU
DAWN

Cheyne Capital Management (UK)’s Day One Biopharmaceuticals DAWN Stock Holding History

Cheyne Capital Management (UK)’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-27,223
Closed -$586K – 30
2022
Q4 		$586K Buy
+27,223
New +$558K 1.02% 33

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cheyne Capital Management (UK)'s DAWN Position: Q1 2023 in Review

Cheyne Capital Management (UK) sold out of Day One Biopharmaceuticals (DAWN) in Q1 2023, closing a stake of 27,223 shares — an estimated $586K sold.

Cheyne Capital Management (UK) first reported a position in DAWN in Q4 2022 and held it in 1 quarter. The position peaked at $586K in Q4 2022. 126 funds tracked by Wall St. Rank hold DAWN as of Q1 2023.

  • Cheyne Capital Management (UK) reported no remaining Day One Biopharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cheyne Capital Management (UK) sold 27,223 Day One Biopharmaceuticals shares in Q1 2023, an estimated $586K.
  • Cheyne Capital Management (UK) first reported a position in Day One Biopharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Cheyne Capital Management (UK)'s Day One Biopharmaceuticals position peaked at $586K in Q4 2022.
  • 126 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2023.

Based on Cheyne Capital Management (UK)'s 13F filing for Q1 2023, filed 3 May 2023.